In today’s Pharmaceutical Executive Daily, the FDA greenlights an expanded use of Breyanzi, Eli Lilly reports Jaypirca met ...
Carvykti’s emerging Phase III data shows that a single early-line infusion can deliver durable, treatment-free remissions ...
Jaypirca is approved for the treatment of adults with relapsed or refractory CLL/SLL who were previously treated with a ...
For Phase III trial planning, two suggestions may have merit. Include sizeable subpopulations that payers cannot easily ...
Scientific advice by EMA. At different stages of your development process, you can go for scientific advice with the EMA. While this service is not free, the associated fees can vary, typically ...
When borders become bottlenecks, leadership—not luck—keeps medicines flowing to the patients that need them. The companies that adapt these new practices will find new opportunities in the changed ...
PE: How are global regulatory agencies adjusting their policies for biosimilars? Woollett: The clear leaders in the space of biosimilar development have been the European agency, the UK, and US FDA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback